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Background: The World Health Organization (WHO) recently produced guidelines advising a treat-all 
policy for HCV to encourage widespread treatment scale-up for achieving HCV elimination. We 
modelled the prevention impact achieved (HCV infections averted [IA]) from initiating this policy 
compared with treating different subgroups at country, regional, and global-levels. We assessed 
what country-level factors affect impact.  
Methods: A dynamic, deterministic HCV transmission model was calibrated to data from global 
systematic reviews and UN datasets to simulate country-level HCV epidemics with ongoing levels of 
treatment. For each country, the model projected the prevention impact (in HCV IA per treatment 
undertaken) of initiating four treatment strategies; either selected randomly (treat-all) or targeted 
among people who inject drugs (PWID), people aged ≥35, or those with cirrhosis. The IA was 
assessed over 20-years. Linear regression was used to identifyidentified associations between IA per 
treatment and demographic factors. 
Results: Eighty-eight countries (85% of the global population) were modelled. Globally, the model 
estimated 0.35 (95% credibility interval [95%CrI]: 0.16-0.61) IA over 20-years for every randomly 
allocated treatment, 0.30 (95%CrI: 0.12-0.53) from treating those aged ≥35, and 0.28 (95%CrI: 0.12-
0.49) for those with cirrhosis. Globally, treating PWID achieved 1.27 (95%CrI: 0.68-2.04) IA per 
treatment. The IA per randomly allocated treatment was positively associated with a country’s 
population growth-rate, and negatively associated with higher HCV prevalence among PWID.  
Conclusions: Appreciable prevention benefits could be achieved from WHO’s treat-all strategy, 
although greater benefits per treatment can be achieved through targeting PWID. Higher impact will 
be achieved in countries with high population growth. 
 
 




Hepatitis C virus (HCV) is a bloodborne infection(1). Globally, over 70 million people are infected 
with HCV(2). An estimated 400,000 people die annually due to HCV-related disease(1, 3, 4).  
Direct-acting antiviral (DAA) treatments have made HCV an easily curable infection(5). In 2016, the 
World Health Organization (WHO) published a Global Health Sector Strategy for eliminating HCV as a 
public health threat by 2030(6), setting targets to reduce the incidence of new infections by 80%, 
and HCV-related mortality by 65%. Meeting these targets requires governments to efficiently 
allocate resources for treating HCV infections, especially where DAA prices are high or resources are 
low(7).  
Historically the emphasis has been on treating people with advanced liver disease(8). However, a 
wider allocation of treatment is required to eliminate HCV. To encourage widespread treatment 
scale-up, WHO produced guidelines in 2018 advising that countries should allow access to HCV 
treatment for all infected individuals: a “treat-all” strategy(9). This HCV treatment strategy will 
produce clinical benefits, such as reducing the risks of severe liver disease(10), and should also 
prevent new infections from occurring through treating individuals with ongoing transmission 
risk(11). Previous analyses have considered who should be treated to achieve greatest morbidity and 
mortality benefits(12-14), whilst other analyses have considered the cost-effectiveness of different 
treatment strategies(13). However, these analyses have generally not included prevention benefits 
unless they focussed on people who inject drugs (PWID), assuming these benefits would be 
negligible when not treating such high-risk groups(15). To help countries understand the overall 
benefits of WHO’s new treat-all policy, it is important to evaluate its prevention benefits and 
determine how country-level demographic and epidemiological differences could affect the 
prevention benefits achieved. 
Indeed, HCV epidemics vary widely between countries, with most of the HCV burden in high-income 
countries being due to needle and syringe sharing among people who inject drugs (PWID)(16, 17), 
while medical and community risk factors are important in most low and middle-income countries 
(LMICs)(18, 19). These epidemic differences will affect the prevention benefits achieved from a 
treat-all strategy.  
We use dynamic HCV transmission modelling to determine the HCV infections averted (IA) per DAA 
treatment at a global, regional, and country-level for a random treat-all strategy, comparing it to 
treating other subgroups, and evaluating how the impact achieved depends on different country-
specific factors. While other studies have investigated the morbidity and mortality benefits from 
different treatment allocations(13, 14), this study focuses on modelling the prevention of 
subsequent chronic HCV infections, comparing a treat-all policy to treating just PWID, individuals 






A dynamic, deterministic HCV transmission model was used to simulate each country-level HCV 
epidemic among the general population and PWID, incorporating population growth, age 
demographics, and HCV progression. Three age groups were modelled: 0–14, 15–34, and ≥35–year 
olds, with the middle age group selected to approximate the age range that individuals start 
injecting, using information from Degenhardt et al(20). New-borns enter the youngest group and age 
through the age groups. Adults (≥15 years) were stratified into individuals who had never injected 
drugs, PWID currently (referred to as PWID henceforth), and people who previously injected drugs 
(see supplementary Fig. 1 for a schematic diagram describing ageing and injecting drug use [IDU]). 
Only young adults (15–34-year olds) were assumed to initiate injecting, with PWID ceasing injecting 
at a fixed rate to become people who previously injected drugs.  
Most individuals enter the model susceptible to infection, with HCV transmission either occurring 
due to injecting drug use (IDU) among PWID, or due to other risk factors among all individuals, 
representing medical/community risk factors. However, due to mother-to-child transmission of HCV, 
some individuals enter the model chronically infected with HCV(21). Once infected, individuals either 
spontaneously clear their infection and return to the susceptible class or develop life-long chronic 
infection. Chronically infected individuals progress through different HCV-related disease stages 
(chronic, compensated cirrhosis, and decompensated cirrhosis) with increased HCV-related mortality 
for individuals with decompensated cirrhosis.  
Modelled HCV treatment can occur at rates dependent on the stage of infection, age, and injecting 
status. A proportion of treated individuals achieve a sustained virologic response (SVR), whereupon 
they become susceptible to re-infection (re-infection is assumed to occur at the same rate as 
primary infection, supplementary Fig. 2 gives a schematic of disease progression), whereas the 
remainder do not achieve SVR and remain chronically infected. Following successful treatment, no 
further disease progression occurs if they had chronic infection(22), but continued slower disease 
progression occurs among those with cirrhosis(22). All individuals die at age-specific death rates, 
with PWID experiencing elevated death due to drug-related mortality(23).  
Model parameterization  
The model was parameterized and calibrated using country-specific data from recent systematic 
reviews and United Nations (UN) datasets(2, 20, 24-32). Information on population sizes, age 
distributions, fertility rates, and mortality rates came from UN datasets, whilst HIV prevalence data 
(used solely for calculating the HCV vertical transmission rate which varies by HIV status, see the 
supplementary materials) were taken from the World Bank(33). Estimates for the proportion of the 
population that are PWID (among adults: 0.03%-4.19%) and antibody prevalence of HCV among 
PWID (5.5%-97.1%) and the general population (0.1%-13.1%) came from recent systematic 
reviews(2, 20), and other reviews where necessary (see supplementary materials). Table 1 gives the 
country-level prevalence estimates. Only USA, Egypt, and France have “two robust surveys”(2) 
(national general population cross-sectional surveys; supplementary materials give more 
information), with these data being used to model the dynamics of their HCV epidemics. For 
country-level HCV prevalence estimates (PWID and general population), antibody prevalence 
estimates were taken from reviews, and then adjusted using region-specific viraemic proportions(34, 
35) to estimate the prevalence of chronic infection in the survey year. Country-level data (regional 
estimates used if no country-level data) on the current duration of injecting from the systematic 
 
 
review by Degenhardt(20) were used to estimate the duration of injecting until cessation, applying 
wide uncertainty bounds (-50% to +100%) to account for uncertainty in how this variable relates to 
the real duration till cessation of injecting.  
Historical treatment numbers were taken from a paper examining progress towards the WHO 2030 
elimination targets(36) and a series of papers on the historical epidemiology of HCV in different 
countries(37-40). However, data for some countries were taken from other sources, discussed fully 
in the supplement. Little data are available on treatment numbers among PWID, so for simplicity we 
assumed similar levels of treatment in this group. Where data on treatment numbers were 
unavailable, then no treatments were assumed to occur. All key parameters had uncertainty, with 
bounds generally obtained directly from studies. Where uncertainty bounds were not available, a 
±33% uncertainty range was applied, corresponding to the average level of uncertainty for 
parameters with uncertainty bounds. 
Model calibration 
The model was calibrated to 88 countries, accounting for 85% of the global population, 92% of the 
total population in high-income countries (HIC), and 83% in LMICs (2016 World Bank categories). The 
modelling only covered 43% of sub-Saharan Africa’s population, 62% of the Middle East and North 
Africa, and 64% of Latin America, whilst covering >95% of the population of the remaining regions 
(supplementary Fig 3).  
A four-step calibration method, using different sub-models, was used to calibrate the full model to 
data for each country, from 1990 onwards. For each step, we randomly sampled the various model 
parameters and calibration data from their uncertainty bounds, and then estimated other unknown 
model parameters through calibrating sequential sub-models. Samples were generated until 1000 
full model fits were obtained for each country, with runs being rejected if they could not fit the 
calibration data described below.  
In brief, for each sampled parameter set, we first used a population growth sub-model (sub-model 1) 
to calculate the average country-specific population growth rates between 1990-2015, calibrating to 
population sizes in 2015. Sub-model 1 was then adapted to include age demographics (sub-model 2) 
to estimate age-specific death rates in 2015, calibrating to data on the proportion of the population 
in the age-groups 0-14, 15-34, and ≥35 years. Sub-model 2 was then further adapted to include IDU 
(sub-model 3) to estimate initiation rates into IDU by calibrating to the country’s population 
proportion of PWID among adults. Lastly, sub-model 3 was further extended to the full model to 
include HCV infection. Sampled and previously fitted parameters were used in the full model to 
estimate HCV transmission rates for PWID and the general population, calibrated to chronic 
prevalence estimates for the specific year where data was available for each country (between 1994-
2015, with only four countries having pre-2000 estimates). The population growth rates between 
1990 and 2015, age-specific death rates, the rate individuals initiate injecting, and HCV transmission 
rates for the general population and PWID were fitted, whilst all other parameters were taken from 
the literature (see supplementary table 3 for fitted parameters and supplementary tables 1 and 2 for 
model parameters informed by the literature, including their sources). Individual transmission risks 
in the general population (eg. due to unsafe medical injections) are not explicitly modelled as data to 
calibrate a global model with these parameters are unavailable. Therefore, we assume that the 
general population HCV transmission is due to a combination of medical (eg. unsafe medical 
 
 
injections), social (eg. circumcision), and community (eg. barbering) factors(19, 41, 42). The 
supplementary materials fully describe the calibration methods and the model equations.  
Due to global improvements in blood bank screening(43), and reductions in the re-use of medical 
syringes(19), country-level HCV epidemics were assumed to be declining over time. Consistent with a 
recent review and modelling of the global HCV epidemics over time(2), we assumed that the general 
population HCV prevalence in each country was decreasing by just over 1% per year, with wide 
sampling ranges (no decrease to 150% of this decrease) being associated with this estimate due to 
uncertainty in the data used to produce this decrease. This assumption was tested in sensitivity 
analyses. Based on synthesised data from Degenhardt’s review(20), we assumed the HCV prevalence 
among PWID was stable between 1990 and the time of each countries HCV prevalence estimate. 
Similarly, the proportion of adults that are PWID was also assumed to be stable, except for Sub-
Saharan African and Eastern European countries where it was assumed to be low in 1990 (25% of 
the recent country estimate) due to evidence suggesting IDU in these regions expanded later than in 
other settings(44).  
Model analyses 
The 1000 full model fits for each country were run over 2018-2038, firstly with that country’s 
baseline level of treatment (counterfactual projections) and then with 50 additional individuals being 
treated in 2018, with the difference in the number of new infections between the paired runs being 
divided by 50 to give the IA per additional treatment over 20-years. Fifty treatments were chosen to 
give an estimate of the initial prevention benefit of further treatment scale-up while being small 
enough not to alter each country’s ongoing epidemic trajectory. This gives an estimate of the initial 
prevention benefit of further treatment scale-up. Scenarios assumed the treated individuals were 
either selected randomly from all infected individuals, or selected from PWID, people with cirrhosis, 
or people ≥35 years old (infected individuals can overlap between categories). For each scenario and 
country, projections across the 1000 model fits were used to produce 95% credibility intervals 
(95%CrI) for all impact estimates. For each scenario, regional and global estimates of the IA per 
treatment were produced by weighting country-level estimates by that country’s relative burden of 
HCV compared to the modelled regional and global burdens. 
Univariable and multivariable regression models investigated which country-level characteristics 
(current population growth rate, population-attributable fraction of IDU to HCV transmission (the 
percentage of new HCV infections prevented 2018-2038 if the additional transmission risk among 
PWID was reduced to zero(45)), population proportion of PWID among adults, average duration of 
IDU, HCV prevalence among PWID and the general population) were associated with the number of 
IA per randomly allocated treatment and per treatment among PWID.  
Sensitivity analyses 
Sensitivity analyses considered the effect of specific assumptions in the model: assuming stable HCV 
epidemics instead of decreasing epidemics, assuming a recent increase in IDU in USA(46) in line with 
the on-going opioid epidemic, assuming longer-term epidemics of IDU in SSA and Eastern Europe 
instead of them recently evolving, assuming treatment rates are halved among PWID and doubled 
among people with cirrhosis (but overall allocating the same number of treatments), and assuming 
HCV epidemic trajectories vary based on regional data. We estimated the prevention impact of on-
 
 
going levels of treatment in each country by comparing the impact achieved over 20 years due to the 
treatments undertaken in 2018, compared to if they had not occurred in that year, but had in 
subsequent years. We examined the IA per treatment when only including the 66 countries with ≥2 
of the key prevalence parameters scored as moderate or better (supplementary table 7). 
The supplementary materials further discuss methods and the rationale underlying these 





Globally, the model estimates 0.35 (95%CrI: 0.16, 0.61) IA per treatment over the next 20-years from 
treating people randomly. China, India, Nigeria, Pakistan, and Russia, which contain around 52% of 
infected individuals in the modelled countries, drive this global estimate. The estimated IA varies 
substantially across regions and countries (Fig 1; Table 2). The region with the lowest IA per 
randomly allocated treatment is Eastern Europe, 0.06 (95%CrI: -0.03, 0.20), while sub-Saharan Africa 
has the highest, 0.75 (95%CrI: 0.45, 1.10).  
Table 2 and Fig 1 show the prevention benefit of randomly allocating treatment compared to 
targeting treatment to PWID, patients with cirrhosis, or people aged ≥35. Globally, treating PWID 
achieves the most prevention impact with 1.27 (95%CrI: 0.68, 2.04) IA per treatment. This ranges 
from as much as 4.82 (95%CrI: 1.98, 6.86) in Madagascar, to negative in Mauritius (–0.52 [95%CrI: –
0.60, –0.14]) due to high levels of re-infection of PWID, although overall numbers of infected 
individuals still reduce because of the additional individuals cured through treatment. Globally, the 
IA per treatment given to individuals with cirrhosis (0.28 [95%CrI: 0.12, 0.49]) or are aged ≥35 years 
(0.30 [95%CrI: 0.12, 0.53]) is less but similar to what is achieved from randomly allocating treatment.  
Determinants of impact 
The IA per randomly allocated treatment (Table 3) is positively associated with a country’s 
population growth-rate (Fig 2a) and the proportion of adults that are PWID, whereas it is negatively 
associated with the HCV prevalence in the general population and PWID (Fig 2b). The multivariable 
regression model’s R2-value is 0.58, indicating these variables explain most of the variation in 
estimated IA between countries.  
Similarly, the number of IA per treatment allocated to PWID was positively associated with a 
country’s population growth-rate (Fig 3a) and population proportion of PWID, and negatively 
associated with the prevalence of HCV among PWID (Fig 3b) and the general population 
(multivariable R2-value: 0.77). Allocating treatment to PWID resulted in negative IA in eight (8%) 
countries, which had higher (≥61%) chronic HCV prevalence among PWID resulting in high modelled 
re-infection rates.  
Sensitivity analyses 
Sensitivity analyses (supplementary tables 10 and 11) show each strategy averts more infections if 
the general population HCV prevalence in each country is stable (0.55 [95%CrI: 0.36, 0.77] IA per 
treatment with random allocation) instead of decreasing (baseline projections). When assuming 
different regional epidemic trajectories, the global IA per randomly allocated treatment increases to 
0.65 [95%CrI: 0.30, 1.10] as some countries were assumed to have stable or increasing epidemics. 
Assuming background treatment rates are halved among PWID and doubled for people with 
cirrhosis reduces theproduces a similar number of IA per extra randomly allocated treatment (0.21 
34 [95%CrI: 0.0814, 0.4060]) compared with the baseline projections. There are more IA per 
randomly allocated treatment when assuming increasing IDU in the USA since 2010(46) (1.02 
[95%CrI: 0.30, 2.26] vs 0.60 [95%CrI: 0.24, 1.16] with a stable proportion of PWID). 
Supplementary table 12 gives the projected number of IA from ongoing treatment rates in 2018 
(around 1.5 million treatments globally) compared to if no treatments were given in 2018 but 
 
 
resumed in 2019. This suggests that from these 1.5 million treatments, 525,764 (95%CrI: 243,948, 
980,523) chronic HCV infections would be averted over the next 20 years, with similar numbers of IA 
per treatment being seen for each country and globally (0.34, 95%CI: 0.16, 0.63) as previously 
estimated for 50 randomly allocated treatments in 2017. 
When only including the countries with ≥2 key prevalence parameters scored as moderate or better, 




Our modelling suggests that one infection will be prevented over the next 20-years for every three 
randomly allocated HCV treatments undertaken globally. The number of HCV infections that are 
averted will vary by region and country, with twenty randomly allocated treatments being needed to 
prevent one infection in Eastern Europe, but less than two in sub-Saharan Africa. Targeting 
treatment to people aged ≥35 or with cirrhosis is likely to produce similar prevention benefits. 
Targeting PWID could achieve greater impact, with over one infection being prevented for every 
PWID treated globally but with impact varying considerably by country and region. Results suggest 
the prevention impact of randomly allocating treatment or treating PWID will be greater in countries 
with high population growth but will be reduced in countries with high HCV prevalence among 
PWID, due to greater re-infection following treatment.  
Strengths and limitations 
This analysis’s strength is the simulation of many country-level HCV epidemics covering 85% of the 
world’s population. The differing role of IDU to each modelled HCV epidemic is captured, and 
differences in population demographics and growth. However, due to data limitations, over half of 
the world’s countries are not represented, overwhelmingly LMICs, including only eight countries in 
Sub-Saharan Africa, possibly affecting regional and global results.  
This study, commissioned by the WHO to focus on the prevention benefits of a treat-all policy, does 
not consider morbidity or mortality benefits. These outcomes have been considered in previous 
economic models, which emphasise the importance of treating individuals with cirrhosis for reducing 
the burden of liver-related deaths(13, 14). This model does not consider the impact of scaling up 
prevention interventions (eg. opiate substitution treatment [OST] and needle and syringe programs 
[NSP]) as the focus was the prevention benefits of treatment. 
The modelling of so many countries necessitated the use of a generalizable model structure and 
standardized algorithm for calibrating the model to each country’s epidemic. The model does not 
account for country’s varying genotype(34), however, evidence suggests that new DAA regimens are 
pan-genotypic so this should not affect the results(47). HIV co-infection was not included in the 
model except for its effect on mother-to-child transmission(21). HIV co-infection will probably 
reduce survival in some countries, although recent increases in HIV treatment coverage has reduced 
this(48). We did not model transmission among men who have sex with men (MSM). This is unlikely 
to affect the results as although HCV prevalence among MSM is higher than among the general 
population, it is much lower than in PWID and partially due to IDU(49). Our model did not include 
 
 
population migration due to data limitations. Migration could be a significant source of new HCV 
infections in some countries(50) (although possibly less than expected(51)), which could affect the 
prevention benefits of treatment. Our model gives general insights on the prevention benefits of 
treatment, and its variability and determinants, giving impetus to undertaking more detailed 
country-specific modelling. 
Regarding historical treatment rates, numbers were unavailable for some countries, were frequently 
only available for one year, and were not stratified by IDU status or disease stage, necessitating 
various assumptions discussed in the supplementary materials and tested in sensitivity analyses. 
Countries are also at varying stages of treatment scale-up(7), therefore the extra 50 treatments 
given may impact differently across settings. We examined this in a sensitivity analysis on the impact 
of on-going treatment rates, suggesting similar IA per treatment. 
The biggest limitation was the lack of high-quality data for some countries on the population 
proportion of PWID, and the prevalence of HCV in the general population and PWID. Countries with 
at least one estimate for each of these parameters from existing systematic reviews were included in 
this analysis; however, some data were old, used ambiguous methods, or had uncertain findings. 
Supplementary table 7 shows 46% of countries modelled had a general population HCV prevalence 
estimate with a low score(2). This was the case for 20% of country estimates for HCV prevalence 
among PWID(20), and 39% of estimates for the proportion of adults that inject drugs(20). Data and 
modelling for countries with higher-scored data estimates should be viewed with more confidence, 
with results from these countries giving a similar IA per randomly allocated treatment. Issues of data 
quality are partly due to the illicit and stigmatised nature of injecting, so estimates of PWID 
population sizes are often obtained indirectly. Additionally, there was little information on the on-
going dynamics of HCV epidemics in most countries, with only three countries (Egypt, France, and 
USA) having robust data(2) (two surveys with similar methodology) on this, which our analyses 
showed could affect the number of IA(52). The main systematic reviews contributing data to this 
analysis were published in 2017, but most national data were older meaning they could pre-date 
recent changes that could affect transmission, such as upturns in injection-related HCV epidemics as 
has occurred in the USA(46). Due to these limitations, the models may not include recent changes in 
HCV epidemics. The effect of this was investigated in the USA, with sensitivity analyses suggesting 
greater IA when assuming an increased initiation of IDU after 2010. The model was not fit to age-
specific HCV prevalence data due to a lack of data on this for many countries modelled. Where 
available, it was not necessarily robust enough to use, particularly for the youngest age group where 
the number of survey participants were often low or the age group was excluded entirely. These 
analyses highlight the importance of improving country-level information on the on-going trajectory 
of HCV epidemics to better understand the likely impact of treatment scale-up; this will also be 
crucial for assessing progress to the WHO HCV elimination targets.  
Comparison to other studies 
To our knowledge, this study is the first to evaluate the prevention impact of different HCV 
treatment allocation strategies across global settings, the first to produce a global estimate for the IA 
per treatment, and the first to determine how country-level factors affect the impact achieved. 
Other modelling analyses have considered the prevention benefits of HCV treatment among PWID, 
MSM, and the general population(12, 13, 15, 52-59). Some analyses of PWID HCV epidemics have 
 
 
also suggested that less prevention benefit will be achieved in settings with higher or increasing HCV 
prevalence among PWID(12, 13, 46, 60). However, no study has undertaken similar analyses for 
generalized HCV epidemic settings.     
Implications 
These analyses show that globally, a moderate prevention impact (one infection prevented per three 
treatments undertaken) can be achieved with a treat-all strategy, with greatest benefit achieved in 
countries with high population growth. These findings are useful for policy-makers as they provide 
an understanding of the prevention benefits of widespread treatment scale-up when planning for 
the WHO 2030 HCV elimination targets(6). The analyses suggest that countries in some regions, such 
as sub-Saharan Africa and South Asia, could achieve greater prevention benefits from scaling up 
treatment than other regions, such as Eastern Europe and Latin America, due to having growing 
populations and generalized epidemics. However, many countries lack the resources to treat 
HCV(61), or screening may present a barrier to treatment scale-up due to their HCV epidemics being 
generalised(16). This issue will be particularly pertinent for countries with high burdens of other 
infectious diseases, where policy-makers may focus their resources on more acute diseases rather 
than HCV. Only with substantial donor support, or considerable improvements in access to HCV DAA 
therapies and diagnostic tests, will such countries be able to substantially scale-up treatment for 
HCV.  
Importantly, our analyses also re-emphasized the prevention benefits of targeting PWID, as PWID 
were the subgroup for whom treatment produced the most IA globally and in most countries. This is 
due to the higher likelihood of PWID transmitting HCV relative to other subgroups(62). However, 
PWID comprise only a fraction of the overall HCV burden globally(63), and a very small fraction of 
both incidence and prevalence for some countries such as Nigeria. Therefore,so any elimination 
strategy must also target other groups, such as those with a history of receiving blood transfusions, 
especially in settings with high rates of infection due to nosocomial factors, such as Pakistan and 
Egypt(64, 65). Additionally, if HCV prevalence is high among PWID then no infections may be averted 
from moderate treatment levels among PWID, due to high re-infection rates. In these scenarios, 
treatment rates must be high among PWID, and/or other HCV prevention interventions for PWID 
(OST and NSP) need to be scaled up to reduce re-infection risks(66). Either way, these insights 
emphasize the need to allocate resources to treating PWID, either due to the greater prevention 
benefits achieved and/or to gain control of the epidemic among PWID; crucial for achieving 
elimination. 
For preventing onwards transmission, this paper’s findings support WHO’s new guidelines for a 
treat-all strategy(9), with special emphasis also being placed on treating PWID for whom the most 
prevention benefit is achieved. However, in many settings, particularly low- or middle-income 
countries, targeting treatment solely to PWID would not be enough to meet the WHO’s elimination 
target for incidence. A treat-all strategy Such a strategy would reduce practical obstacles to 
treatment, such as screening to prioritise individuals with advanced disease, and could be 
considered more equitable by allowing all those who seek treatment to access it. There are other 
issues to consider, mainly surrounding resourcing for the costs of testing and treatment and 
ensuring that those with progressed disease are treated. If these issues can be dealt with, our 
 
 
analyses suggest that a widespread treat-all strategy will achieve considerable prevention benefits in 
most settings.    
 
 
Table 1: Country-level sampled ranges for antibody prevalence of HCV among the general 
population and people who inject drugs (PWID), as well as the prevalence of injecting drug use and 
their duration of injecting drug use. Prevalence ranges are taken from the literature, and where they 
were not available ranges of ±33% are used. Ranges for injecting duration are taken as 50% and 
200% of the estimate for the current duration of injecting.  





 Prevalence    
Country 
Anti-HCV among general 
population (%) 
Anti-HCV prevalence 
among PWID (%) 
% of adults that are 
PWID 
Injecting drug use 
duration (years)6 
Afghanistan 2007 1.10% (0.40%, 1.92%) 37.8% (27.5%, 48.1%) 0.80% (0.50%, 1.09%) 6.8 (3.4, 13.6) 
Albania 2008 3.00% (2.01%, 3.99%) 34.0% (27.5%, 41.0%) 0.42% (0.28%, 0.56%) 12.4 (6.2, 24.8) 
Argentina 2007 1.50% (0.32%, 2.00%) 54.6% (51.1%, 58.1%) 0.29% (0.29%, 0.30%) 13.2 (6.6, 26.4) 
Armenia 2010 4.00% (2.68%, 5.32%) 42.7% (29.3%, 56.1%) 0.62% (0.41%, 1.35%) 11.8 (5.9, 23.6) 
Australia 2012 1.30% (1.20%, 1.85%) 53.5% (50.2%, 56.9%) 0.60% (0.43%, 0.76%) 15.4 (7.7, 30.8) 
Austria 2008 0.50% (0.10%, 0.70%) 60.9% (54.8%, 67.0%) 0.32% (0.22%, 0.42%) 13.0 (6.5, 26.0) 
Azerbaijan 2010 3.70% (2.48%, 4.92%) 62.1% (47.1%, 77.2%) 0.61% (0.49%, 0.74%) 8.8 (4.4, 17.6) 
Bangladesh 2010 1.26% (0.20%, 2.23%) 33.9% (22.4%, 45.4%) 0.07% (0.06%, 0.07%) 6.0 (3.0, 12.0) 
Belarus 2006 1.26% (0.86%, 2.85%) 58.3% (43.3%, 73.3%) 0.59% (0.22%, 0.96%) 10.9 (5.5, 21.8) 
Belgium 1994 0.87% (0.12%, 1.10%) 58.4% (47.0%, 69.7%) 0.35% (0.24%, 0.49%) 13.3 (6.7, 26.6) 
Bosnia 2008 0.10% (0.07%, 0.13%) 39.9% (27.5%, 52.4%) 0.17% (0.11%, 0.23%) 15.0 (7.5, 30.0) 
Brazil 2007 1.38% (1.12%, 1.64%) 63.9% (60.5%, 67.3%) 0.67% (0.51%, 0.87%) 13.2 (6.6, 26.4) 
Bulgaria 2012 1.50% (0.70%, 2.43%) 68.7% (64.3%, 73.0%) 0.38% (0.30%, 0.45%) 9.0 (4.5, 18.0) 
Canada 2011 0.96% (0.61%, 1.34%) 70.6% (60.1%, 93.9%) 0.39% (0.31%, 0.47%) 14.3 (7.2, 28.6) 
China 2015 1.21% (0.93%, 1.49%) 43.1% (27.5%, 58.6%) 0.25% (0.19%, 0.31%) 7.1 (3.6, 14.2) 
Croatia 2011 0.90% (0.50%, 1.40%) 36.7% (28.1%, 45.3%) 0.23% (0.18%, 0.29%) 13.5 (6.8, 27.0) 
Cyprus 2001 0.56% (0.45%, 1.87%) 49.7% (44.4%, 55.0%) 0.08% (0.04%, 0.12%) 8.8 (4.4, 17.6) 
Czech Republic 2012 0.57% (0.20%, 0.70%) 18.3% (14.5%, 22.1%) 0.64% (0.61%, 0.67%) 11.8 (5.9, 23.6) 
Denmark 2007 0.63% (0.48%, 0.72%) 42.6% (36.1%, 49.1%) 0.45% (0.35%, 0.52%) 18.2 (9.1, 36.4) 
Egypt 2015 10.00% (9.50%, 10.50%) 49.4% (35.8%, 63.0%) 0.21% (0.13%, 0.28%) 5.2 (2.6, 10.4) 
Estonia 2013 1.97% (1.50%, 2.00%) 79.2% (67.4%, 91.0%) 0.94% (0.69%, 1.73%) 8.1 (4.1, 16.2) 
Finland 2013 0.68% (0.60%, 0.90%) 73.7% (69.9%, 77.2%) 0.46% (0.41%, 0.67%) 12.4 (6.2, 24.8) 
France 2004 0.84% (0.45%, 1.10%) 64.0% (60.8%, 67.0%) 0.20% (0.16%, 0.23%) 12.4 (6.2, 24.8) 
FYROM 2008 0.50% (0.34%, 0.67%) 62.2% (59.4%, 64.9%) 0.16% (0.11%, 0.21%) 12.4 (6.2, 24.8) 
Georgia 2015 5.40% (4.51%, 6.32%) 69.1% (58.0%, 80.2%) 4.19% (0.48%, 7.90%) 14.1 (7.1, 28.2) 
Germany 2012 0.58% (0.30%, 0.90%) 65.0% (60.6%, 69.4%) 0.24% (0.03%, 0.45%) 13.9 (7.0, 27.8) 
Ghana 2014 2.10% (1.20%, 5.50%) 40.1% (34.8%, 45.4%) 0.05% (0.03%, 0.07%) 10.0 (5.0, 20.0) 
Greece 2011 1.79% (0.50%, 2.61%) 65.7% (61.8%, 69.5%) 0.07% (0.06%, 0.09%) 11.7 (5.9, 23.4) 
Hungary 2014 0.70% (0.40%, 2.70%) 46.4% (30.4%, 62.8%) 0.06% (0.03%, 0.08%) 9.6 (4.8, 19.2) 
Iceland 2013 0.41% (0.33%, 0.48%) 63.0% (59.8%, 66.2%) 0.24% (0.16%, 0.32%) 7.0 (3.5, 14.0) 
India 2013 0.84% (0.50%, 1.50%) 40.0% (33.9%, 46.1%) 0.02% (0.01%, 0.03%) 7.2 (3.6, 14.4) 
Indonesia 2007 0.80% (0.10%, 1.70%) 89.2% (85.3%, 92.3%) 0.11% (0.09%, 0.13%) 7.1 (3.6, 14.2) 
Iran 2006 0.50% (0.20%, 1.00%) 44.1% (28.2%, 59.9%) 0.28% (0.19%, 0.37%) 8.2 (4.1, 16.4) 
Ireland 2010 0.70% (0.67%, 1.60%) 74.6% (72.3%, 76.9%) 0.27% (0.20%, 0.33%) 12.4 (6.2, 24.8) 
Israel 2006 1.96% (0.90%, 2.10%) 45.3% (38.1%, 52.6%) 0.41% (0.27%, 0.55%) 14.0 (7.0, 28.0) 
Italy 2001 2.43% (1.60%, 7.30%) 57.9% (52.5%, 63.3%) 0.83% (0.57%, 1.14%) 9.0 (4.5, 18.0) 
Japan 2011 0.98% (0.49%, 2.20%) 64.8% (55.0%, 74.5%) 0.47% (0.36%, 0.58%) 7.3 (3.7, 14.6) 
 
 
Kazakhstan 2010 3.20% (1.30%, 4.26%) 58.8% (54.0%, 63.6%) 0.96% (0.64%, 1.42%) 5.0 (2.5, 10.0) 
Kenya 2007 0.76% (0.20%, 1.01%) 16.4% (10.9%, 23.3%) 0.12% (0.03%, 0.20%) 5.3 (2.7, 10.6) 
Kyrgyzstan 2010 2.45% (1.60%, 6.70%) 43.9% (40.6%, 47.2%) 0.74% (0.50%, 1.11%) 6.3 (3.2, 12.6) 
Latvia 2008 2.40% (1.70%, 3.30%) 74.4% (67.6%, 81.2%) 0.92% (0.73%, 1.17%) 9.1 (4.6, 18.2) 
Lebanon 2011 0.21% (0.11%, 0.70%) 23.4% (15.3%, 33.3%) 0.14% (0.09%, 0.19%) 5.2 (2.6, 10.4) 
Libya 2005 1.20% (1.10%, 1.30%) 94.5% (91.5%, 96.7%) 0.05% (0.01%, 0.10%) 5.2 (2.6, 10.4) 
Lithuania 2010 1.96% (1.21%, 2.71%) 41.1% (38.1%, 44.2%) 0.22% (0.12%, 0.34%) 10.0 (5.0, 20.0) 
Luxembourg 2006 1.34% (0.56%, 1.61%) 81.3% (76.2%, 85.8%) 0.57% (0.45%, 0.69%) 12.4 (6.2, 24.8) 
Madagascar 2004 1.20% (0.75%, 1.72%) 5.5% (2.1%, 9.0%) 0.12% (0.02%, 0.59%) 7.8 (3.9, 15.6) 
Malaysia 2011 1.90% (0.30%, 7.70%) 67.1% (62.9%, 71.1%) 1.33% (1.11%, 1.56%) 13.9 (7.0, 27.8) 
Malta 2010 0.36% (0.26%, 0.60%) 25.2% (13.1%, 37.3%) 0.26% (0.17%, 0.35%) 12.4 (6.2, 24.8) 
Mauritius 2010 2.10% (1.41%, 2.79%) 97.1% (96.0%, 98.1%) 0.78% (0.39%, 1.54%) 14.0 (7.0, 28.0) 
Mexico 2000 1.40% (1.10%, 1.60%) 95.3% (93.3%, 97.3%) 0.18% (0.12%, 0.25%) 16.1 (8.1, 32.2) 
Moldova 2010 4.46% (2.30%, 4.46%) 50.1% (34.1%, 66.1%) 0.40% (0.25%, 0.54%) 12.7 (6.4, 25.4) 
Montenegro 2008 1.20% (0.80%, 1.60%) 43.4% (39.8%, 47.1%) 0.40% (0.27%, 0.53%) 6.0 (3.0, 12.0) 
Morocco 2008 1.20% (1.10%, 1.93%) 53.9% (33.7%, 74.0%) 0.13% (0.07%, 0.20%) 10.0 (5.0, 20.0) 
Mozambique 2011 1.30% (0.10%, 6.90%) 67.1% (62.9%, 71.2%) 0.20% (0.00%, 0.41%) 7.8 (3.9, 15.6) 
Myanmar 2009 1.69% (0.95%, 2.66%) 29.5% (26.9%, 32.2%) 0.48% (0.32%, 0.65%) 3.4 (1.7, 6.8) 
Nepal 2010 0.64% (0.43%, 0.85%) 44.5% (30.8%, 58.2%) 0.20% (0.19%, 0.21%) 5.2 (2.6, 10.4) 
Netherlands 2009 0.22% (0.07%, 0.37%) 55.3% (49.7%, 60.9%) 0.03% (0.02%, 0.04%) 12.4 (6.2, 24.8) 
New Zealand 2013 1.43% (0.81%, 2.15%) 71.9% (63.2%, 80.6%) 0.73% (0.49%, 0.97%) 15.4 (7.7, 30.8) 
Nigeria 2012 2.20% (2.10%, 2.50%) 5.8% (3.5%, 8.9%) 0.35% (0.23%, 0.47%) 8.0 (4.0, 16.0) 
Norway 2012 0.55% (0.45%, 0.70%) 64.8% (60.4%, 69.1%) 0.24% (0.21%, 0.29%) 14.0 (7.0, 28.0) 
Pakistan 2008 4.80% (4.70%, 5.10%) 36.5% (5.1%, 79.1%) 0.37% (0.32%, 0.42%) 5.1 (2.6, 10.2) 
Philippines 2003 0.94% (0.33%, 2.00%) 35.2% (15.9%, 54.5%) 0.04% (0.03%, 0.05%) 6.8 (3.4, 13.6) 
Poland 2009 0.86% (0.59%, 1.14%) 58.7% (55.1%, 66.2%) 0.27% (0.18%, 0.36%) 14.4 (7.2, 28.8) 
Portugal 1995 1.50% (0.47%, 2.87%) 87.7% (80.5%, 95.0%) 0.22% (0.19%, 0.25%) 12.4 (6.2, 24.8) 
Romania 2007 3.23% (2.94%, 3.55%) 83.8% (80.6%, 87.1%) 0.62% (0.46%, 0.84%) 9.8 (4.9, 19.6) 
Russia 2010 4.10% (1.16%, 5.60%) 68.7% (59.6%, 77.9%) 1.78% (0.94%, 2.71%) 7.6 (3.8, 15.2) 
Saudi Arabia 2011 0.51% (0.41%, 0.61%) 77.8% (73.2%, 81.9%) 0.20% (0.13%, 0.27%) 5.2 (2.6, 10.4) 
Senegal 2009 1.00% (0.00%, 4.60%) 39.3% (31.1%, 47.9%) 0.08% (0.05%, 0.11%) 7.8 (3.9, 15.6) 
Serbia 2008 0.50% (0.34%, 0.67%) 25.9% (22.1%, 29.7%) 0.49% (0.41%, 0.58%) 8.8 (4.4, 17.6) 
Slovakia 2011 1.40% (0.88%, 1.98%) 56.1% (35.6%, 76.7%) 0.49% (0.35%, 0.89%) 11.8 (5.9, 23.6) 
Slovenia 2015 0.40% (0.30%, 0.50%) 30.5% (26.4%, 34.5%) 0.42% (0.30%, 0.55%) 12.4 (6.2, 24.8) 
Spain 2012 1.50% (0.40%, 2.64%) 71.0% (69.5%, 72.5%) 0.08% (0.05%, 0.10%) 11.2 (5.6, 22.4) 
Sweden 2012 0.56% (0.47%, 0.69%) 81.7% (79.6%, 83.6%) 0.13% (0.03%, 0.62%) 21.0 (10.5, 42.0) 
Switzerland 1998 1.55% (0.80%, 1.75%) 74.6% (69.3%, 79.4%) 0.24% (0.19%, 0.29%) 12.4 (6.2, 24.8) 
Syria 2004 2.80% (0.60%, 3.72%) 60.5% (40.5%, 80.5%) 0.07% (0.04%, 0.09%) 5.2 (2.6, 10.4) 
Taiwan 2000 3.28% (2.50%, 8.60%) 91.0% (89.5%, 92.4%) 0.30% (0.20%, 0.40%) 15.5 (7.8, 31.0) 
Tajikistan 2010 3.06% (1.10%, 6.70%) 61.3% (56.8%, 65.6%) 0.45% (0.30%, 0.66%) 5.9 (3.0, 11.8) 
Tanzania 2013 2.70% (0.20%, 7.80%) 27.7% (22.4%, 33.5%) 1.24% (0.72%, 1.76%) 4.3 (2.2, 8.6) 
Thailand 2014 0.94% (0.75%, 3.66%) 88.5% (82.6%, 92.9%) 0.11% (0.03%, 0.18%) 7.3 (3.7, 14.6) 
Tunisia 1996 1.27% (0.20%, 1.70%) 29.1% (25.7%, 32.6%) 0.21% (0.14%, 0.29%) 5.2 (2.6, 10.4) 
Turkey 2009 0.95% (0.60%, 2.10%) 44.9% (41.7%, 48.2%) 0.42% (0.28%, 0.56%) 4.0 (2.0, 8.0) 
Turkmenistan 2010 5.55% (1.10%, 6.70%) 60.6% (46.2%, 75.0%) 0.40% (0.27%, 0.53%) 5.9 (3.0, 11.8) 
UK 2005 0.50% (0.40%, 0.75%) 46.0% (36.8%, 55.2%) 0.39% (0.38%, 0.42%) 10.0 (5.0, 20.0) 
 
 
Ukraine 2010 3.58% (0.86%, 4.46%) 53.9% (49.2%, 58.7%) 0.97% (0.52%, 1.79%) 12.2 (6.1, 24.4) 
Uruguay 2010 1.00% (0.67%, 1.33%) 21.9% (19.0%, 24.8%) 0.30% (0.10%, 0.87%) 13.2 (6.6, 26.4) 
USA 2007 1.30% (1.20%, 1.50%) 53.1% (38.1%, 68.0%) 1.40% (0.57%, 1.88%) 16.2 (8.1, 32.4) 
Uzbekistan 2000 13.10% (6.40%, 13.11%) 51.7% (46.8%, 56.6%) 0.47% (0.32%, 0.70%) 5.9 (3.0, 11.8) 




Table 2: The number of chronic hepatitis C virus infections averted per treatment over 20 years 
(2018-2038) for the different treatment allocation scenarios, for each country, region and globally, 
with 95% credibility intervals. 
 
Chronic hepatitis C virus infections averted per treatment for different allocation strategies 
Country 
Random (treat-all) PWID* 
People with 
cirrhosis 
People aged ≥35 
years 
Global 0.35 (0.16, 0.61) 1.27 (0.68, 2.04) 0.28 (0.12, 0.49) 0.30 (0.12, 0.53) 
Central Asia 0.32 (0.14, 0.56) 1.66 (1.25, 2.29) 0.24 (0.09, 0.43) 0.26 (0.08, 0.45) 
Kazakhstan 0.26 (0.18, 0.40) 1.42 (1.08, 2.38) 0.14 (0.08, 0.26) 0.16 (0.08, 0.28) 
Kyrgyzstan 0.42 (0.24, 0.62) 2.14 (1.66, 2.78) 0.30 (0.12, 0.48) 0.30 (0.12, 0.48) 
Tajikistan 0.50 (0.24, 0.76) 1.80 (1.36, 2.32) 0.38 (0.14, 0.60) 0.38 (0.14, 0.60) 
Turkmenistan 0.40 (0.20, 0.64) 1.66 (1.10, 2.40) 0.30 (0.12, 0.50) 0.32 (0.14, 0.54) 
Uzbekistan 0.30 (0.10, 0.56) 1.66 (1.26, 2.22) 0.24 (0.08, 0.44) 0.26 (0.06, 0.46) 
Eastern Europe 0.06 (-0.03, 0.20) 0.14 (-0.10, 0.72) 0.05 (-0.02, 0.14) 0.06 (-0.02, 0.16) 
Armenia 0.12 (0.02, 0.26) 0.50 (0.12, 1.02) 0.08 (0.02, 0.20) 0.08 (0.02, 0.22) 
Azerbaijan 0.24 (0.06, 0.46) 0.28 (-0.08, 0.76) 0.20 (0.06, 0.38) 0.22 (0.06, 0.44) 
Belarus 0.00 (-0.10, 0.14) -0.14 (-0.36, 0.34) 0.00 (-0.06, 0.12) 0.00 (-0.06, 0.14) 
Bosnia 0.00 (-0.12, 0.14) 0.02 (-0.18, 0.32) 0.00 (-0.10, 0.08) 0.00 (-0.10, 0.10) 
Bulgaria 0.02 (-0.04, 0.10) -0.02 (-0.20, 0.50) 0.00 (-0.02, 0.10) 0.02 (-0.02, 0.12) 
Czech Republic 0.80 (0.54, 1.46) 2.48 (1.90, 3.24) 0.50 (0.28, 1.02) 0.60 (0.36, 1.20) 
Estonia 0.40 (0.08, 0.80) 0.68 (0.08, 1.48) 0.28 (0.06, 0.62) 0.32 (0.08, 0.70) 
Georgia 0.40 (0.14, 0.72) 0.74 (0.48, 1.06) 0.32 (0.12, 0.58) 0.34 (0.12, 0.62) 
Hungary 0.20 (0.06, 0.42) 0.94 (0.40, 1.68) 0.16 (0.04, 0.36) 0.18 (0.04, 0.38) 
Latvia 0.06 (-0.06, 0.26) 0.08 (-0.20, 0.70) 0.04 (-0.04, 0.18) 0.06 (-0.04, 0.20) 
Lithuania 0.18 (0.08, 0.36) 0.88 (0.62, 1.30) 0.14 (0.06, 0.30) 0.16 (0.06, 0.32) 
Moldova 0.14 (0.02, 0.30) 0.34 (-0.04, 0.88) 0.10 (0.00, 0.24) 0.12 (0.00, 0.28) 
Poland 0.10 (0.00, 0.26) 0.16 (-0.02, 0.38) 0.08 (0.00, 0.22) 0.10 (0.00, 0.26) 
Romania -0.02 (-0.08, 0.06) -0.26 (-0.38, 0.24) 0.00 (-0.06, 0.06) 0.00 (-0.06, 0.08) 
Russia 0.02 (-0.06, 0.14) 0.02 (-0.22, 0.66) 0.02 (-0.04, 0.08) 0.02 (-0.04, 0.10) 
Slovakia 0.08 (-0.06, 0.28) 0.12 (-0.24, 0.70) 0.04 (-0.04, 0.20) 0.06 (-0.04, 0.24) 
Ukraine 0.10 (0.06, 0.22) 0.48 (0.30, 1.02) 0.06 (0.02, 0.16) 0.08 (0.04, 0.18) 
Australasia 0.26 (0.13, 0.49) 0.54 (0.29, 1.00) 0.21 (0.11, 0.41) 0.22 (0.11, 0.43) 
Australia 0.24 (0.14, 0.40) 0.54 (0.34, 0.92) 0.20 (0.12, 0.34) 0.20 (0.12, 0.34) 
New Zealand 0.34 (0.06, 0.90) 0.52 (0.06, 1.34) 0.26 (0.04, 0.72) 0.30 (0.04, 0.80) 
East & Southeast Asia 0.26 (0.09, 0.49) 1.26 (0.70, 2.08) 0.19 (0.04, 0.39) 0.21 (0.04, 0.44) 
China 0.24 (0.10, 0.44) 1.40 (0.82, 2.26) 0.18 (0.04, 0.36) 0.20 (0.04, 0.40) 
Indonesia 0.12 (-0.04, 0.36) -0.10 (-0.26, 0.10) 0.12 (-0.02, 0.30) 0.12 (-0.02, 0.34) 
Japan 0.46 (0.18, 0.88) 1.30 (0.68, 2.18) 0.32 (0.10, 0.66) 0.36 (0.12, 0.72) 
Malaysia 0.32 (0.10, 0.56) 0.58 (0.26, 0.94) 0.26 (0.06, 0.46) 0.28 (0.08, 0.52) 
Myanmar 0.30 (0.18, 0.50) 2.56 (1.96, 3.88) 0.18 (0.06, 0.34) 0.18 (0.06, 0.38) 
Philippines 0.38 (0.16, 0.64) 2.14 (1.14, 3.68) 0.30 (0.12, 0.52) 0.34 (0.14, 0.56) 
Taiwan 0.06 (-0.02, 0.26) -0.08 (-0.24, 0.14) 0.06 (-0.02, 0.22) 0.06 (0.00, 0.26) 
Thailand 0.16 (0.00, 0.38) 0.00 (-0.18, 0.22) 0.14 (0.00, 0.32) 0.16 (0.00, 0.36) 
Viet Nam 0.24 (0.06, 0.44) 0.90 (0.40, 1.58) 0.18 (0.02, 0.34) 0.20 (0.02, 0.38) 
South Asia 0.49 (0.25, 0.76) 1.86 (0.96, 2.75) 0.41 (0.21, 0.63) 0.43 (0.21, 0.67) 
Afghanistan 0.86 (0.34, 1.34) 2.14 (1.16, 3.36) 0.62 (0.16, 1.02) 0.66 (0.18, 1.02) 
Bangladesh 0.40 (0.20, 0.66) 1.90 (1.14, 2.92) 0.32 (0.16, 0.54) 0.34 (0.16, 0.56) 
India 0.44 (0.22, 0.70) 1.74 (1.26, 2.48) 0.38 (0.20, 0.58) 0.40 (0.20, 0.64) 
Iran 0.32 (0.10, 0.64) 0.98 (0.38, 1.86) 0.22 (0.04, 0.46) 0.26 (0.06, 0.52) 
 
 
Nepal 0.30 (0.08, 0.56) 1.06 (0.46, 1.94) 0.22 (0.02, 0.42) 0.24 (0.04, 0.46) 
Pakistan 0.58 (0.32, 0.86) 2.08 (0.50, 3.14) 0.48 (0.26, 0.72) 0.50 (0.26, 0.74) 
North America 0.58 (0.22, 1.13) 1.04 (0.44, 2.00) 0.46 (0.18, 0.90) 0.50 (0.20, 0.99) 
Canada 0.30 (-0.06, 0.72) 0.48 (-0.28, 1.28) 0.24 (-0.04, 0.58) 0.26 (-0.04, 0.64) 
USA 0.60 (0.24, 1.16) 1.08 (0.50, 2.06) 0.48 (0.20, 0.92) 0.52 (0.22, 1.02) 
Western Europe 0.32 (0.13, 0.68) 0.91 (0.51, 1.62) 0.24 (0.09, 0.53) 0.27 (0.1, 0.58) 
Albania 0.10 (0.04, 0.24) 0.96 (0.72, 1.36) 0.08 (0.02, 0.18) 0.08 (0.02, 0.20) 
Austria 0.66 (0.38, 1.08) 1.24 (0.72, 1.94) 0.50 (0.26, 0.84) 0.56 (0.28, 0.94) 
Belgium 0.26 (0.06, 0.70) 0.74 (0.20, 1.36) 0.18 (0.02, 0.54) 0.20 (0.04, 0.60) 
Croatia 0.16 (0.06, 0.32) 1.00 (0.70, 1.44) 0.10 (0.04, 0.24) 0.12 (0.04, 0.26) 
Cyprus 0.32 (0.10, 0.56) 1.36 (0.88, 1.96) 0.24 (0.06, 0.44) 0.28 (0.08, 0.50) 
Denmark 0.38 (0.28, 0.52) 1.06 (0.80, 1.42) 0.26 (0.16, 0.40) 0.30 (0.20, 0.46) 
FYROM 0.08 (0.04, 0.22) 0.32 (0.20, 0.48) 0.04 (0.02, 0.18) 0.06 (0.02, 0.20) 
Finland 0.06 (-0.02, 0.16) 0.14 (-0.04, 0.68) 0.04 (-0.02, 0.10) 0.04 (0.00, 0.12) 
France 0.28 (0.14, 0.60) 0.76 (0.46, 1.40) 0.22 (0.12, 0.46) 0.24 (0.12, 0.50) 
Germany 0.40 (0.18, 0.80) 0.88 (0.54, 1.38) 0.30 (0.12, 0.62) 0.34 (0.14, 0.70) 
Greece 0.22 (0.04, 0.42) 0.42 (0.20, 0.70) 0.18 (0.04, 0.34) 0.20 (0.04, 0.40) 
Iceland 0.26 (0.18, 0.38) 0.70 (0.44, 1.16) 0.18 (0.14, 0.26) 0.20 (0.14, 0.28) 
Ireland 0.22 (0.06, 0.44) 0.42 (0.14, 0.80) 0.18 (0.04, 0.36) 0.20 (0.04, 0.40) 
Italy 0.24 (0.08, 0.50) 0.86 (0.54, 1.60) 0.16 (0.06, 0.36) 0.18 (0.06, 0.40) 
Luxembourg 0.94 (0.28, 1.60) 1.50 (0.54, 2.52) 0.76 (0.22, 1.30) 0.82 (0.24, 1.38) 
Malta 0.36 (0.20, 0.64) 1.12 (0.60, 2.18) 0.28 (0.16, 0.48) 0.32 (0.18, 0.54) 
Montenegro 0.12 (0.08, 0.22) 1.00 (0.70, 2.00) 0.06 (0.04, 0.14) 0.06 (0.04, 0.16) 
Netherlands 0.28 (0.12, 0.58) 1.00 (0.38, 1.76) 0.24 (0.10, 0.48) 0.26 (0.10, 0.52) 
Norway 0.64 (0.40, 0.94) 1.32 (0.90, 1.82) 0.50 (0.28, 0.74) 0.56 (0.32, 0.82) 
Portugal 0.24 (0.06, 0.46) 0.44 (-0.14, 0.80) 0.20 (0.06, 0.40) 0.22 (0.06, 0.42) 
Serbia 0.30 (0.22, 0.38) 1.42 (1.12, 2.20) 0.14 (0.10, 0.20) 0.18 (0.12, 0.24) 
Slovenia 0.52 (0.38, 0.74) 1.50 (1.14, 2.18) 0.36 (0.24, 0.54) 0.42 (0.28, 0.62) 
Spain 0.20 (0.08, 0.50) 0.70 (0.38, 1.12) 0.18 (0.06, 0.44) 0.20 (0.06, 0.46) 
Sweden 0.62 (0.10, 1.18) 0.92 (0.00, 1.52) 0.52 (0.08, 1.00) 0.56 (0.10, 1.08) 
Switzerland 0.38 (0.18, 0.64) 0.86 (0.52, 1.32) 0.30 (0.16, 0.52) 0.34 (0.16, 0.56) 
UK 0.50 (0.22, 1.22) 0.96 (0.38, 2.04) 0.36 (0.14, 0.94) 0.40 (0.16, 1.04) 
Sub Saharan Africa 0.75 (0.45, 1.10) 2.30 (1.38, 3.38) 0.60 (0.33, 0.89) 0.57 (0.33, 0.86) 
Ghana 0.66 (0.40, 0.98) 1.94 (1.40, 2.64) 0.54 (0.32, 0.80) 0.54 (0.34, 0.80) 
Kenya 0.68 (0.38, 1.04) 3.74 (2.22, 5.82) 0.50 (0.26, 0.80) 0.48 (0.26, 0.76) 
Madagascar 0.76 (0.44, 1.16) 4.82 (1.98, 6.86) 0.60 (0.34, 0.94) 0.62 (0.36, 0.94) 
Mauritius -0.10 (-0.26, 0.10) -0.52 (-0.60, -0.14) -0.06 (-0.18, 0.12) -0.04 (-0.18, 0.14) 
Mozambique 0.62 (0.28, 0.96) 0.54 (0.20, 1.00) 0.50 (0.22, 0.80) 0.44 (0.20, 0.72) 
Nigeria 0.76 (0.46, 1.12) 2.02 (1.04, 3.18) 0.62 (0.38, 0.92) 0.60 (0.36, 0.88) 
Senegal 0.76 (0.46, 1.14) 1.94 (1.16, 2.98) 0.62 (0.38, 0.94) 0.62 (0.38, 0.90) 
Tanzania 0.84 (0.54, 1.18) 3.20 (2.34, 4.26) 0.62 (0.30, 0.90) 0.58 (0.30, 0.90) 
Latin America 0.19 (0.03, 0.40) 0.18 (-0.01, 0.40) 0.15 (0.02, 0.32) 0.17 (0.02, 0.37) 
Argentina 0.24 (0.06, 0.46) 0.60 (0.36, 0.90) 0.18 (0.04, 0.36) 0.22 (0.04, 0.42) 
Brazil 0.22 (0.08, 0.40) 0.42 (0.20, 0.68) 0.16 (0.04, 0.32) 0.18 (0.04, 0.36) 
Mexico 0.12 (-0.08, 0.36) -0.50 (-0.60, -0.38) 0.12 (-0.04, 0.32) 0.14 (-0.04, 0.36) 
Uruguay 0.28 (0.12, 0.46) 1.60 (1.16, 2.28) 0.20 (0.06, 0.34) 0.22 (0.08, 0.40) 
Middle East & North Africa 0.20 (0.09, 0.41) 0.84 (0.50, 1.39) 0.18 (0.08, 0.35) 0.19 (0.08, 0.36) 
Egypt 0.18 (0.08, 0.38) 0.78 (0.46, 1.26) 0.18 (0.08, 0.34) 0.18 (0.08, 0.34) 
Israel 0.62 (0.38, 0.88) 1.86 (1.40, 2.42) 0.48 (0.28, 0.70) 0.54 (0.32, 0.78) 
Lebanon 0.92 (0.58, 1.44) 4.22 (3.14, 6.14) 0.66 (0.36, 1.04) 0.74 (0.42, 1.16) 
Libya 0.20 (0.00, 0.42) -0.24 (-0.38, -0.06) 0.18 (0.02, 0.36) 0.20 (0.02, 0.40) 
 
 
Morocco 0.34 (0.16, 0.54) 1.16 (0.54, 1.84) 0.28 (0.12, 0.46) 0.30 (0.14, 0.48) 
Saudi Arabia 0.08 (-0.02, 0.40) 0.12 (-0.08, 0.46) 0.08 (-0.02, 0.34) 0.08 (-0.02, 0.38) 
Syria 0.38 (0.18, 0.66) 0.82 (0.20, 1.70) 0.32 (0.14, 0.54) 0.34 (0.16, 0.56) 
Tunisia 0.26 (0.12, 0.50) 1.56 (1.20, 2.08) 0.16 (0.04, 0.34) 0.18 (0.06, 0.40) 
Turkey 0.22 (0.12, 0.42) 1.26 (0.92, 2.32) 0.10 (0.04, 0.30) 0.12 (0.04, 0.34) 
*PWID: people who inject drugs 
 
 
Table 3: The univariable and multivariable linear regression coefficients, with 95% confidence intervals (CI), showing the associations between demographic 
and epidemiological variables and (a) the number of infections averted per randomly allocated treatment, and (b) the number of infections averted per 
treatment allocated to PWID. 
 
 Infections averted per randomly allocated treatment 
Variable 
Mean (Range) across 
country-level variable 
Univariable regression 
coefficient (95% CI) P-value 
Multivariable regression 
coefficient (95% CI) P-value 
Population growth rate (% increase in population per year)* 0.6% (-0.8%, 3.8%) 0.13 (0.10, 0.17) <0.001 0.13 (0.08, 0.17) <0.001 
General Population chronic HCV prevalence (%)* 1.1% (0.1%, 6.0%) -0.03 (-0.08, 0.03) 0.332 -0.07 (-0.12, -0.02) 0.008 
PWID chronic HCV prevalence (%)* 37.2% (3.9%, 72.7%) -0.009 (-0.012, -0.006) <0.001 -0.007 (-0.010, -0.004) <0.001 
Population proportion of PWID (% of adults that are PWID)* 0.44% (0.02%, 3.95%) -0.00 (-0.10, 0.10) 0.998 0.12 (0.02, 0.21) 0.017 
Population Attributable Fraction of HCV due to IDU* 68.9% (1.6%, 100.0%) -0.003 (-0.004, -0.001) 0.001 -0.001 (-0.003, 0.001) 0.465 
Injecting duration (years)** 13.1 (4.4, 24.8) -0.01 (-0.02, 0.00) 0.196 0.01 (-0.00, 0.02) 0.097 
  Infections averted per PWID allocated treatment 
Population growth rate (% increase in population per year)* 0.6% (-0.8%, 3.8%) 0.46 (0.29, 0.63) <0.001 0.20 (0.07, 0.33) 0.004 
General Population chronic HCV prevalence (%)* 1.1% (0.1%, 6.0%) -0.07 (-0.28, 0.14) 0.499 -0.25 (-0.40, -0.10) 0.002 
PWID antibody HCV prevalence (%)* 37.2% (3.9%, 72.7%) -0.058 (-0.067, -0.049)  <0.001 -0.047 (-0.056, -0.039) <0.001 
Population proportion of PWID (% of adults that are PWID)* 0.44% (0.02%, 3.95%) -0.14 (-0.53, 0.25) 0.471 0.34 (0.06, 0.63) 0.019 
Population Attributable Fraction of HCV due to IDU* 68.9% (1.6%, 100.0%) -0.014 (-0.020, -0.008) <0.001 -0.005 (-0.011, 0.000) 0.060 
Injecting duration (years)** 13.1 (4.4, 24.8) -0.08 (-0.12, -0.04) <0.001 -0.02 (-0.05, 0.00) 0.063 
 *Per percentage point increase; **per year of injecting duration 




Fig 1: Chronic HCV infections averted per HCV treatment over 20 years globally, and by region 






Fig 2: Scatter plots of the univariable associations between the number of HCV infections averted 
(over 20 years) per treatment given randomly, and a country’s population growth rate (2a), or the 





























































































Fig 3: Scatter plots of the univariable associations between the number of HCV infections averted 
(over 20 years) per treatment given to people who inject drugs (PWID), and either a country’s 
population growth rate (3a), or the antibody HCV prevalence among people who inject drugs (PWID) 



















































































1. World Health Organization. Hepatitis C Fact sheet 2017 [Available from: 
http://www.who.int/mediacentre/factsheets/fs164/en/. 
2. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of 
hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161-
76. 
3. Hallager S, Ladelund S, Christensen PB, Kjaer M, Thorup Roege B, Gronbaek KE, et al. Liver-
related morbidity and mortality in patients with chronic hepatitis C and cirrhosis with and without 
sustained virologic response. Clin Epidemiol. 2017;9:501-16. 
4. Schietroma I, Scheri GC, Pinacchio C, Statzu M, Petruzziello A, Vullo V. Hepatitis C Virus and 
Hepatocellular Carcinoma: Pathogenetic Mechanisms and Impact of Direct-Acting Antivirals. Open 
Virol J. 2018;12:16-25. 
5. Florian J, Mishra P, Arya V, Harrington P, Connelly S, Reynolds KS, et al. Direct-acting antiviral 
drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now. Clin Pharmacol 
Ther. 2015;98(4):394-402. 
6. World Health Organization. Global Health Sector Strategy on Viral Hepatitis 2016-2021. 
2016. 
7. World Health Organization. Access to hepatitis C treatment 2018. 2018. 
8. World Health Organization. Guidelines for the screening, care and treatment of persons with 
hepatitis C infection. Geneva; 2014. 
9. World Health Organization. Guidelines for the care and treatment of persons diagnosed with 
chronic hepatitis C virus infection. 2018. 
10. Butt AA, Yan P, Simon TG, Abou-Samra AB. Effect of 
Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir and Ledipasvir/Sofosbuvir Regimens on Survival 
Compared With Untreated Hepatitis C Virus-Infected Persons: Results From ERCHIVES. Clin Infect 
Dis. 2017;65(6):1006-11. 
11. Boerekamps A, Van den Berk GE, Fanny LN, Leyten EM, Van Kasteren ME, van Eeden A, et al. 
Declining HCV incidence in Dutch HIV positive men who have sex with men after unrestricted access 
to HCV therapy. Clin Infect Dis. 2017. 
12. Martin NK, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ, et al. Cost-
effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology. 
2012;55(1):49-57. 
13. Martin NK, Vickerman P, Dore GJ, Grebely J, Miners A, Cairns J, et al. Prioritization of HCV 
treatment in the direct-acting antiviral era: An economic evaluation. J Hepatol. 2016;65(1):17-25. 
14. Deuffic-Burban S, Boursier J, Leroy V, Yazdanpanah Y, Castera L, Mathurin P. Are targeted 
treatment recommendations in chronic hepatitis C tailored to diagnostic methods of fibrosis? J 
Hepatol. 2017;66(2):304-12. 
15. Bennett H, McEwan P, Sugrue D, Kalsekar A, Yuan Y. Assessing the Long-Term Impact of 
Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship 
between Treatment Uptake and Efficacy on Future Infections. PLoS One. 2015;10(5):e0125846. 
16. Degenhardt L, Charlson F, Stanaway J, Larney S, Alexander LT, Hickman M, et al. Estimating 
the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and 
hepatitis B: findings from the Global Burden of Disease Study 2013. Lancet Infect Dis. 
2016;16(12):1385-98. 
17. Negro F. Epidemiology of hepatitis C in Europe. Dig Liver Dis. 2014;46 Suppl 5:S158-64. 
18. Tohme RA, Holmberg SD. Transmission of hepatitis C virus infection through tattooing and 
piercing: a critical review. Clin Infect Dis. 2012;54(8):1167-78. 
19. Pepin J, Abou Chakra CN, Pepin E, Nault V, Valiquette L. Evolution of the global burden of 




20. Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global 
prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, 
and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017. 
21. Benova L, Mohamoud YA, Calvert C, Abu-Raddad LJ. Vertical transmission of hepatitis C 
virus: systematic review and meta-analysis. Clin Infect Dis. 2014;59(6):765-73. 
22. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C 
virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational 
studies. Ann Intern Med. 2013;158(5 Pt 1):329-37. 
23. Mathers BM, Degenhardt L, Bucello C, Lemon J, Wiessing L, Hickman M. Mortality among 
people who inject drugs: a systematic review and meta-analysis. Bulletin of the World Health 
Organization. 2013;91:102-23. 
24. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype 
distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1 Suppl):S45-57. 
25. Hope VD, Eramova I, Capurro D, Donoghoe MC. Prevalence and estimation of hepatitis B and 
C infections in the WHO European Region: a review of data focusing on the countries outside the 
European Union and the European Free Trade Association. Epidemiol Infect. 2014;142(2):270-86. 
26. Riou J, Ait Ahmed M, Blake A, Vozlinsky S, Brichler S, Eholie S, et al. Hepatitis C virus 
seroprevalence in adults in Africa: a systematic review and meta-analysis. J Viral Hepat. 
2016;23(4):244-55. 
27. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011;17(2):107-
15. 
28. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. Global 
epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. 
Lancet. 2008;372(9651):1733-45. 
29. Reid SR. Injection drug use, unsafe medical injections, and HIV in Africa: a systematic review. 
Harm Reduct J. 2009;6:24. 
30. Mumtaz GR, Weiss HA, Thomas SL, Riome S, Setayesh H, Riedner G, et al. HIV among People 
Who Inject Drugs in the Middle East and North Africa: Systematic Review and Data Synthesis. Plos 
Med. 2014;11(6). 
31. Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug 
users. International Journal of Drug Policy. 2007;18(5):352-8. 
32. United Nations Department of Economic and Social Affairs Population Division.  [Available 
from: https://esa.un.org/unpd/wpp/DataQuery. 
33. The World Bank. Prevalence of HIV, females (% ages 15-24). 2016. 
34. Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of 
hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus 
genotypes. World J Gastroentero. 2016;22(34):7824-40. 
35. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C 
infection: a systematic review of longitudinal studies. J Viral Hepat. 2006;13(1):34-41. 
36. Hill AM, Nath S, Simmons B. The road to elimination of hepatitis C: analysis of cures versus 
new infections in 91 countries. J Virus Erad. 2017;3(3):117-23. 
37. Bruggmann P, Berg T, Ovrehus AL, Moreno C, Brandao Mello CE, Roudot-Thoraval F, et al. 
Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat. 2014;21 Suppl 
1:5-33. 
38. Saraswat V, Norris S, de Knegt RJ, Sanchez Avila JF, Sonderup M, Zuckerman E, et al. 
Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2. J Viral Hepatitis. 
2015;22:6-25. 
39. Liakina V, Hamid S, Tanaka J, Olafsson S, Sharara AI, Alavian SM, et al. Historical 
epidemiology of hepatitis C virus (HCV) in select countries - volume 3. J Viral Hepatitis. 2015;22:4-20. 
40. Maaroufi A, Vince A, Himatt SM, Mohamed R, Fung J, Opare-Sem O, et al. Historical 




41. Pepin J, Lavoie M, Pybus OG, Pouillot R, Foupouapouognigni Y, Rousset D, et al. Risk factors 
for hepatitis C virus transmission in colonial Cameroon. Clin Infect Dis. 2010;51(7):768-76. 
42. Schmidt M. Barbering, a probable risk factor for HCV transmission. Am J Gastroenterol. 
1998;93(10):1999. 
43. Prati D. Transmission of hepatitis C virus by blood transfusions and other medical 
procedures: a global review. J Hepatol. 2006;45(4):607-16. 
44. European Monitoring Centre for Drugs and Drug Addiction. Trends in Injecting Drug use in 
Europe. 2010. 
45. Trickey A, Fraser H, Lim AG, Peacock A, Colledge S, Walker JG, et al. The contribution of 
injecting drug use as a risk factor for Hepatitis C virus transmission globally, regionally, and at 
country level: a modelling study. Lancet Gastroenterol Hepatol. 2018. 
46. Fraser H, Zibbell J, Hoerger T, Hariri S, Vellozzi C, Martin NK, et al. Scaling-up HCV prevention 
and treatment interventions in rural United States-model projections for tackling an increasing 
epidemic. Addiction. 2018;113(1):173-82. 
47. Hezode C. Pan-genotypic treatment regimens for hepatitis C virus: Advantages and 
disadvantages in high- and low-income regions. J Viral Hepat. 2017;24(2):92-101. 
48. UNAIDS. Global AIDS Update 2016. 2016. 
49. Martin NK, Vickerman P, Dore GJ, Hickman M. The hepatitis C virus epidemics in key 
populations (including people who inject drugs, prisoners and MSM): the use of direct-acting 
antivirals as treatment for prevention. Curr Opin Hiv Aids. 2015;10(5):374-80. 
50. Vriend HJ, Van Veen MG, Prins M, Urbanus AT, Boot HJ, De Coul ELM. Hepatitis C virus 
prevalence in The Netherlands: migrants account for most infections. Epidemiology and Infection. 
2013;141(6):1310-7. 
51. Uddin G, Shoeb D, Solaiman S, Marley R, Gore C, Ramsay M, et al. Prevalence of chronic viral 
hepatitis in people of south Asian ethnicity living in England: the prevalence cannot necessarily be 
predicted from the prevalence in the country of origin. J Viral Hepat. 2010;17(5):327-35. 
52. Ayoub HH, Abu-Raddad LJ. Impact of treatment on hepatitis C virus transmission and 
incidence in Egypt: A case for treatment as prevention. J Viral Hepat. 2017;24(6):486-95. 
53. Cousien A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, Dhersin JS, Yazdanpanah Y. 
Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who 
inject drugs. Hepatology. 2016;63(4):1090-101. 
54. Harris RJ, Martin NK, Rand E, Mandal S, Mutimer D, Vickerman P, et al. New treatments for 
hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England. J Viral 
Hepat. 2016;23(8):631-43. 
55. Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Can antiviral 
therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A 
modeling analysis of its prevention utility. J Hepatol. 2011;54(6):1137-44. 
56. Martin NK, Thornton A, Hickman M, Sabin C, Nelson M, Cooke GS, et al. Can Hepatitis C Virus 
(HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who 
Have Sex With Men in the United Kingdom? Epidemiological and Modeling Insights. Clin Infect Dis. 
2016;62(9):1072-80. 
57. Lim AG, Qureshi H, Mahmood H, Hamid S, Davies CF, Trickey A, et al. Curbing the hepatitis C 
virus epidemic in Pakistan: the impact of scaling up treatment and prevention for achieving 
elimination. Int J Epidemiol. 2018. 
58. Durham DP, Skrip LA, Bruce RD, Vilarinho S, Elbasha EH, Galvani AP, et al. The Impact of 
Enhanced Screening and Treatment on Hepatitis C in the United States. Clin Infect Dis. 
2016;62(3):298-304. 
59. Heffernan A, Cooke GS, Nayagam S, Thursz M, Hallett TB. Scaling up prevention and 
treatment towards the elimination of hepatitis C: a global mathematical model. Lancet. 2019. 
60. de Vos AS, Kretzschmar ME. Benefits of hepatitis C virus treatment: a balance of preventing 




61. Graham CS, Swan T. A path to eradication of hepatitis C in low- and middle-income 
countries. Antiviral Res. 2015;119:89-96. 
62. Islam N, Krajden M, Shoveller J, Gustafson P, Gilbert M, Buxton JA, et al. Incidence, risk 
factors, and prevention of hepatitis C reinfection: a population-based cohort study. Lancet 
Gastroenterol. 2017;2(3):200-10. 
63. Grebely J, Larney S, Peacock A, Colledge S, Leung J, Hickman M, et al. Global, regional, and 
country-level estimates of hepatitis C infection among people who have recently injected drugs. 
Addiction. 2018. 
64. Lim AG, Qureshi H, Mahmood H, Hamid S, Davies CF, Trickey A, et al. Curbing the hepatitis C 
virus epidemic in Pakistan: the impact of scaling up treatment and prevention for achieving 
elimination. Int J Epidemiol. 2018;47(2):550-60. 
65. Omran D, Alboraie M, Zayed RA, Wifi MN, Naguib M, Eltabbakh M, et al. Towards hepatitis C 
virus elimination: Egyptian experience, achievements and limitations. World J Gastroenterol. 
2018;24(38):4330-40. 
66. Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, et al. Needle syringe programmes 
and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. 
Cochrane Db Syst Rev. 2017(9). 
 
